These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 37439881)

  • 1. Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review.
    Cowart K; Singleton J; Carris NW
    Clin Ther; 2023 Nov; 45(11):1099-1104. PubMed ID: 37451914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
    Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
    [No Abstract]   [Full Text] [Related]  

  • 3. Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis.
    Zhao L; Liu Y; Cao Z; Wang J; Huo X
    Iran J Public Health; 2023 May; 52(5):903-912. PubMed ID: 37484718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.
    Rikhi R; Shapiro MD
    Eur Cardiol; 2023; 18():e45. PubMed ID: 37456766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and hotspots in familial hypercholesterolemia: A bibliometric systematic review from 2002 to 2022.
    Chen L; Peng H; Wang BL; Yu WY; Ding XH; Gao MX; Yu Y
    Medicine (Baltimore); 2023 Jul; 102(28):e34247. PubMed ID: 37443479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
    Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
    Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
    Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
    Mohammadi KA; Brackin T; Schwartz GG; Steg PG; Szarek M; Manvelian G; Pordy R; Fazio S; Geba GP
    Cancer Med; 2023 Aug; 12(16):16859-16868. PubMed ID: 37458138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions.
    Mitkowski P; Witkowski A; Stępińska J; Banach M; Jankowski P; Gąsior M; Wita K; Bartuś S; Burchardt P; Farkowski MM; Gierlotka M; Gil R; Leszek P; Sterliński M; Szymański P; Tajstra M; Tycińska A; Wojakowski W
    Kardiol Pol; 2023; 81(7-8):818-823. PubMed ID: 37489830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients.
    Matta A; Rabès JP; Taraszkiewicz D; Carrié D; Roncalli J; Ferrières J
    Front Cardiovasc Med; 2023; 10():1182554. PubMed ID: 37539087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
    Miao J; Hu C; Tang J; Wang W; Wang Y; Men R; Yang L; Gu L; Yoshida N; Czerniak R
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1036-1044. PubMed ID: 37443412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies.
    Ma MM; Xu YY; Sun LH; Cui WJ; Fan M; Zhang S; Liu L; Wu LZ; Li LC
    Int J Gen Med; 2024; 17():2055-2063. PubMed ID: 38751493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary.
    Vohra LI; Rizwan K; Saeed E; Hamza MSA; Ochani S
    Egypt Heart J; 2023 Jul; 75(1):60. PubMed ID: 37439881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.